[1] علی شیری و همکاران. استفاده از ویروسها بهعنوان حامل برای انتقال دارو. تازههای بیوتکنولوژی سلولی-ملکولی. ۱۳۹۳؛ (۱۷): ۵۸-۶۷.
[2] Alemzadeh, E., et al., Plant virus nanoparticles: Novel and robust nanocarriers for drug delivery and imaging. Colloids and Surfaces B: Biointerfaces, 2018. 167: p. 20–27.
[3] ابراهیمی سعیده و عینی گندمانی امید. کاربرد ویروسهای گیاهی در بیونانوتکنولوژی. مهندسی ژنتیک و ایمنی زیستی. ۱۳۹۵؛ (۲) ۲۱۱-۲۲۴.
[4] Ohtake, N., et al., Low pH-triggered model drug molecule release from virus-like particles. ChemBioChem, 2010. 11: p. 959–962.
[5] Galaway, F.A., and P.G. Stockley, MS2 virus-like particles: a robust, semisynthetic targeted drug delivery platform. Molecular Pharmaceutics, 2013. 10(1): p. 59–68.
[6] Mejía-Méndez, J.L., et al., Virus-like Particles: Fundamentals and Biomedical Applications. International Journal of Molecular Sciences, 2022. 23(15): p. 8579.
[7] Kheirvari, M., H. Liu, and E. Tumban, Virus-like particle vaccines and platforms for vaccine development. Viruses, 2023. 15(5): p. 1109.
[8] Shoeb, E., and K. Hefferon, Future of cancer immunotherapy using plant virus-based nanoparticles. Future-science.OA, 2019. 5(7): p. FSO401.
[9] Ikwuagwu, B., and D. Tullman-Ercek, Virus-like particles for drug delivery: a review of methods and applications. Current Opinion in Biotechnology, 2022. 78: p. 102785.
[10] Gupta, R., et al., Platforms, advances, and technical challenges in virus-like particles-based vaccines. Frontiers in Immunology, 2023. 14: p. 1123805.
[11] همتی دیناروند م.ف و همکاران. استفاده از ذرات شبهویروسی (VLPs) در تولید واکسن. فصلنامه علمی-پژوهشی دانشگاه علوم پزشکی لرستان. ۱۴۰۰؛ ۲۳(۵): ۶۴-۵۲.
[12] Nooraei, S., et al., Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. Nanobiotechnology, 2021. 19(59): p. 1–27.
[13] Tariq, H., et al., Virus-like particles: revolutionary platforms for developing vaccines against emerging infectious diseases. Frontiers in Microbiology, 2022. 12: p. 790121.
[14] Lua, L.H., et al., Bioengineering viruslike particles as vaccines. Biotechnology and Bioengineering, 2014. 111(3): p. 425–440.
[15] Cervera, L., et al., Generation of HIV-1 Gag VLPs by transient transfection of HEK 293 suspension cell cultures using an optimized animal-derived component free medium. Journal of Biotechnology, 2013. 166(4): p. 152–165.
[16] Hu, G., et al., Generation and immunogenicity of porcine circovirus type 2 chimeric virus-like particles displaying porcine reproductive and respiratory syndrome virus GP5 epitopeB. Vaccine, 2016. 34(16): p. 1896–1903.
[17] Yan, D., et al., The application of virus-like particles as vaccines and biological vehicles. Applied Microbiology and Biotechnology, 2015. 99(24): p. 10415–10432.
[18] López-Macías, C., Virus-like particle (VLP)-based vaccines for pandemic influenza: performance of a VLP vaccine during the 2009 influenza pandemic. Human Vaccines & Immunotherapeutics, 2012. 8(3): p. 411–414.
[19] Jeong, H., and B.L. Seong, Exploiting virus-like particles as innovative vaccines against emerging viral infections. Journal of Microbiology, 2017. 55(3): p. 220–230.
[20] حسینی سید امیر و همکاران. ذرات شبهویروسی: ساختمان، ویژگی و کاربرد آنها در واکسن. مجلهی علمی پزشکی جندیشاپور. ۱۳۹۶؛ ۱۶(۵): ۵۷۵–۵۸۹.
[21] Taghizadeh, M.S., A. Niazi, and A.A. Afsharifar, Virus-like particles (VLPs): A promising platform for combating against Newcastle disease virus. Vaccine: X, 2024. 16: p. 100440.
[22] Zhang, L., et al., Virus-like particles as antiviral vaccine: mechanism, design, and application. Biotechnology and Bioprocess Engineering, 2023. 28(1): p. 1–16.
[23] Shahgolzari, M., H. Dianat-Moghadam, and S. Fiering, Multifunctional plant virus nanoparticles in the next generation of cancer immunotherapies. Seminars in Cancer Biology, 2022. 86(Pt 2): p. 1076–1085.
[24] Biela, P., et al., Programmable polymorphism of a virus-like particle. Communications Materials, 2022. 3(7): p. 1–9.
[25] Caldeira, C., et al., Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines. Viruses, 2020. 12(488): p. 1–20.
[26] Dai, S., H. Wang, and F. Deng, Advances and challenges in enveloped virus-like particle (VLP)-based vaccines. Journal of Immunological Sciences, 2018. 2(2): p. 36–41.
[27] Mohsen, M., et al., Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System. Vaccines, 2018. 6(37): p. 1–12.
[28] Kingston, N.J., et al., Hepatitis B virus-like particles expressing Plasmodium falciparum epitopes induce complement-fixing antibodies against the circumsporozoite protein. Vaccine, 2019. 37(12): p. 1674–84.
[29] Janitzek, C.M., et al., A proof-of-concept study for the design of a VLP-based combinatorial HPV and placental malaria vaccine. Scientific Reports, 2019. 9(1): p. 41522.
[30] Yan, F., et al., Peste des petits Ruminants virus-like particles induce a potent humoral and cellular immune response in goats. Viruses, 2019. 11(10): p. 918.
[31] Earnest-Silveira, L., et al., Characterization of a hepatitis C virus-like particle vaccine produced in a human hepatocyte-derived cell line. Journal of General Virology, 2016. 97(8): p. 1865–1876.
[32] Lagoutte, P., et al., Simultaneous surface display and cargo loading of encapsulin nanocompartments and their use for rational vaccine design. Vaccine, 2018. 36(25): p. 3622–3628.
[33] Hu, Y.M., et al., Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 viruslike particle vaccine: An open-label phase I clinical trial. Human Vaccines & Immunotherapeutics, 2014. 10(2): p. 469–475.
[34] World Health Organization. Vaccines Cecolin,
https://extranet.who.int/pqweb/content/cecolin®. 2021.
[35] Medicago Clinical Trials Update: Avian flu vaccine. Genetic Engineering & Biotechnology News, 2011. 31: p. 61.
[36] Potera, C., Vaccine Manufacturing Gets Boost from Tobacco Plants: Canada-Based Medicago Opens U.S. Facility to Exploit Its Influenza Vaccine Production Method. Genetic Engineering & Biotechnology News, 2012. 32: p. 8–10.
[37] Thanavala, Y., et al., Immunogenicity in humans of an edible vaccine for hepatitis B. Proceedings of the National Academy of Sciences USA, 2005. 102(9): p. 3378–3382.
[38] Yusibov, V., et al., Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine, 2002. 20(25–26): p. 3155–3164.
[39] Tacket, C.O., et al., Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes. Journal of Infectious Diseases, 2000. 182(1): p. 302–305.
[40] Andersson, P., and C. Ostheimer, Combinatorial approaches to enhance anti-tumor immunity: Focus on immune checkpoint blockade therapy. Frontiers in Immunology, 2019. 10: p. 2083.
[41] Christofi, T., et al., Current perspectives in cancer immunotherapy. Cancers, 2019. 11: p. 1472.
[42] Wahid, B., et al., An overview of cancer immunotherapeutic strategies. Immunotherapy, 2018. 10: p. 999–1010.
[43] Muenst, S., et al., The immune system and cancer evasion strategies: Therapeutic concepts. Journal of Internal Medicine, 2016. 279: p. 541–562.
[44] Del Giudice, G., R. Rappuoli, and A.M. Didierlaurent, Correlates of adjuvanticity: A review on adjuvants. Seminars in Immunology, 2018. 39: p. 14–21.
[45] Chang, D., X. Cai, R.A. Consigli, Characterization of the DNA binding properties of polyomavirus capsid protein. Journal of Virology, 1993. 67(10): p. 6327–6331.
[46] Slilaty, S.N., H.V. Aposhian, Gene transfer by polyoma-like particles assembled in a cell-free system. Science, 1983. 220(4598): p. 725–727.
[47] Forstova, J., et al., Polyoma virus pseudocapsids as efficient carriers of heterologous DNA into mammalian cells. Human Gene Therapy, 1995. 6(3): p. 297–306.
[48] Tegerstedt, K., et al., Murine polyomavirus virus-like particles (VLPs) as vectors for gene and immune therapy and vaccines against viral infections and cancer. Anticancer Research, 2005. 25(4): p. 2601–2608.
[49] Alemzadeh, E., K. Izadpanah, and F. Ahmadi, Generation of recombinant protein shells of Johnson grass chlorotic stripe mosaic virus in tobacco plants and their use as drug carrier. Journal of Virological Methods, 2017. 248: p. 148–153.
[50] Alemzadeh, E., et al., Enhanced anti-tumor efficacy and reduced cardiotoxicity of doxorubicin delivered in a novel plant virus nanoparticle. Colloids and Surfaces B: Biointerfaces, 2019. 174: p. 80–86.
[51] Bruckman, M., et al., Tobacco mosaic virus rods and spheres as supramolecular high-relaxivity MRI contrast agents. Journal of Materials Chemistry B, 2013. 1: p. 1482–1490.
